- Home
- CHW vs CELC Comparison
CHW vs CELC Comparison
Compare CHW & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHW
- CELC
- Stock Information
- Founded
- CHW 2007
- CELC 2011
- Country
- CHW United States
- CELC United States
- Employees
- CHW N/A
- CELC N/A
- Industry
- CHW Investment Managers
- CELC Medical Specialities
- Sector
- CHW Finance
- CELC Health Care
- Exchange
- CHW Nasdaq
- CELC Nasdaq
- Market Cap
- CHW 431.1M
- CELC 489.7M
- IPO Year
- CHW N/A
- CELC 2017
- Fundamental
- Price
- CHW $6.83
- CELC $10.93
- Analyst Decision
- CHW
- CELC Strong Buy
- Analyst Count
- CHW 0
- CELC 6
- Target Price
- CHW N/A
- CELC $29.17
- AVG Volume (30 Days)
- CHW 195.2K
- CELC 356.6K
- Earning Date
- CHW 01-01-0001
- CELC 11-14-2024
- Dividend Yield
- CHW 9.27%
- CELC N/A
- EPS Growth
- CHW N/A
- CELC N/A
- EPS
- CHW N/A
- CELC N/A
- Revenue
- CHW N/A
- CELC N/A
- Revenue This Year
- CHW N/A
- CELC N/A
- Revenue Next Year
- CHW N/A
- CELC N/A
- P/E Ratio
- CHW N/A
- CELC N/A
- Revenue Growth
- CHW N/A
- CELC N/A
- 52 Week Low
- CHW $5.07
- CELC $10.35
- 52 Week High
- CHW $6.54
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- CHW 48.22
- CELC 35.65
- Support Level
- CHW $6.64
- CELC $10.35
- Resistance Level
- CHW $6.81
- CELC $13.80
- Average True Range (ATR)
- CHW 0.10
- CELC 0.83
- MACD
- CHW 0.01
- CELC -0.19
- Stochastic Oscillator
- CHW 46.34
- CELC 16.20
About CHW Calamos Global Dynamic Income Fund
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment strategy is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities and alternative investments.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.